Enhertu approved in US for 1L HER2+ metastatic BC

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in combination with pertuzumab as a first‑line treatment for unresectable or metastatic HER2‑positive breast cancer after DESTINY‑Breast09 showed a 44% reduction in risk of progression or death (HR 0.56; 95% CI 0.44–0.71; p<0.0001) and median PFS of 40.7 months versus 26.9 months for standard THP, with a consistent benefit across subgroups and no new safety signals. Granted via Priority Review/Breakthrough designation and reviewed under RTOR and Project Orbis, the regimen is the first new 1L option in more than a decade and could become the new standard of care for roughly 10,000 US patients treated annually in this setting. Commercially, AstraZeneca will pay Daiichi Sankyo a $150m milestone and US sales will be recognised by Daiichi Sankyo, while regulatory reviews and separate filings continue internationally, signaling meaningful near‑term revenue upside if clinical adoption is strong.

Analysis

The FDA has approved AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer based on DESTINY-Breast09 Phase III data. The trial (n=1,157) showed a 44% reduction in risk of progression or death (HR 0.56; 95% CI 0.44-0.71; p<0.0001) and a median progression-free survival of 40.7 months versus 26.9 months for the prior standard THP, with consistent subgroup benefit and no new safety signals reported.

The approval was granted under Priority Review/Breakthrough designations and leveraged FDA RTOR and Project Orbis processes; the commercial arrangement calls for a $150m milestone payment from AstraZeneca to Daiichi Sankyo and US sales of Enhertu to be recognized by Daiichi Sankyo. Approximately 10,000 US patients are treated annually in the first-line HER2-positive metastatic setting, so the label expansion creates a meaningful near-term addressable market and the potential to displace THP as the standard of care.

Key near-term readouts and risks to monitor include the ongoing blinded Enhertu monotherapy arm, pending overall survival data (a secondary endpoint), payer and clinician uptake versus entrenched THP practice, and the outcome of ongoing regulatory reviews internationally (Swissmedic, HSA and others). Commercial upside is clear for Daiichi in the US and strategic benefit for AstraZeneca's ADC platform long term, but final market share and revenue realization will depend on adoption, reimbursement and confirmatory endpoints.

Key Decisions for Investors

• Consider increasing exposure to Daiichi Sankyo to capture near-term US revenue recognition and the $150m milestone payment that is immediately due following FDA approval
• For AstraZeneca, consider a neutral-to-accumulate stance on pullbacks to reflect long-term strategic upside from broader Enhertu indications and ADC platform growth while accounting for the milestone outflow
• Monitor upcoming catalysts—overall survival readout, final PFS from the blinded monotherapy arm, early commercial uptake metrics and international regulatory decisions—and reassess positions after these data are available
• Manage near-term execution risk through position sizing or hedging until payer coverage and initial prescribing trends validate rapid adoption over the longstanding THP standard